Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Towa Pharmaceutical Co ( (JP:4553) ) just unveiled an announcement.
Towa Pharmaceutical plans to issue up to ¥20 billion in Class A preferred shares through a third-party allotment to Development Bank of Japan, alongside partial amendments to its Articles of Incorporation and a corresponding reduction of share capital and legal capital surplus. The funds will be directed toward capital investment and collaboration projects to advance the group’s growth strategy, with the move contingent on shareholder approval and structured preferred terms, including non-voting shares with dividend and option features that aim to strengthen its balance sheet while limiting common shareholder dilution.
The most recent analyst rating on (JP:4553) stock is a Buy with a Yen3500.00 price target. To see the full list of analyst forecasts on Towa Pharmaceutical Co stock, see the JP:4553 Stock Forecast page.
More about Towa Pharmaceutical Co
Towa Pharmaceutical Co., Ltd. is a Japan-based drugmaker focused on developing, manufacturing, and selling pharmaceutical products, with an emphasis on generic medicines. The company operates in the healthcare sector, targeting domestic and international markets where demand for cost-effective treatments and stable drug supply supports long-term growth and capital-intensive investment.
Average Trading Volume: 131,973
Technical Sentiment Signal: Buy
Current Market Cap: Yen190.2B
Learn more about 4553 stock on TipRanks’ Stock Analysis page.